肺癌治疗中的既定、新兴和难以捉摸的分子靶点。
Established, emerging and elusive molecular targets in the treatment of lung cancer.
机构信息
Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
J Pathol. 2018 Apr;244(5):565-577. doi: 10.1002/path.5038. Epub 2018 Feb 14.
Abstract
Although histological subtype still underlies tumour classification and treatment, the recognition that lung cancer is, largely, a genetic disease has prompted a push to reconfigure cancer taxonomies according to molecular criteria. In this review, we discuss established (e.g. EGFR, ALK, ROS1, and programmed cell death 1/programmed death-ligand 1), emerging (e.g. MET, RET, and NTRK) and elusive (e.g. TP53, KRAS, and MYC) molecular targets in the treatment of lung cancer. We synthesize a large and rapidly growing body of literature regarding the discovery and therapeutic inhibition of these targets in lung cancer. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
摘要
尽管组织学亚型仍然是肿瘤分类和治疗的基础，但人们认识到肺癌在很大程度上是一种遗传性疾病，这促使人们根据分子标准重新构建癌症分类法。在这篇综述中，我们讨论了肺癌治疗中已确立的（例如 EGFR、ALK、ROS1 和程序性细胞死亡 1/程序性死亡配体 1）、新兴的（例如 MET、RET 和 NTRK）和难以捉摸的（例如 TP53、KRAS 和 MYC）分子靶点。我们综合了大量关于这些靶点在肺癌中的发现和治疗抑制的快速增长的文献。版权所有©2018 英国和爱尔兰病理学会。由 John Wiley & Sons, Ltd. 出版。
相似文献
1
Established, emerging and elusive molecular targets in the treatment of lung cancer.肺癌治疗中的既定、新兴和难以捉摸的分子靶点。
J Pathol. 2018 Apr;244(5):565-577. doi: 10.1002/path.5038. Epub 2018 Feb 14.
2
The emerging significance of secondary germline testing in cancer genomics.肿瘤基因组学中胚系二次检测的新兴意义。
J Pathol. 2018 Apr;244(5):610-615. doi: 10.1002/path.5031. Epub 2018 Feb 16.
3
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.已知存在突变或重排的晚期非小细胞肺癌的管理：最新证据与治疗方法
Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30.
4
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.针对具有致癌驱动分子改变的肺癌患者的靶向治疗。
J Clin Oncol. 2022 Feb 20;40(6):611-625. doi: 10.1200/JCO.21.01626. Epub 2022 Jan 5.
5
Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.肾细胞癌的基因组分类：迈向泛组学精准个体化肾癌治疗的关键一步
J Pathol. 2018 Apr;244(5):525-537. doi: 10.1002/path.5022. Epub 2018 Feb 14.
6
New ESMO scale ranks mutations as cancer medicine targets.新的欧洲肿瘤内科学会（ESMO）量表将突变列为癌症药物靶点。
Lancet Oncol. 2018 Oct;19(10):e513. doi: 10.1016/S1470-2045(18)30664-8. Epub 2018 Aug 31.
7
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.基于靶向 NGS 检测的肿瘤突变负荷可预测非小细胞肺癌免疫检查点抑制剂的临床获益。
J Pathol. 2020 Jan;250(1):19-29. doi: 10.1002/path.5344. Epub 2019 Oct 24.
8
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.基于下一代测序的肺癌分子诊断特征及其与 PD-L1 表达的关系。
Pathol Res Pract. 2020 Feb;216(2):152797. doi: 10.1016/j.prp.2019.152797. Epub 2019 Dec 23.
9
The molecular pathology of cancer: from pan-genomics to post-genomics.癌症的分子病理学：从泛基因组学到后基因组学。
J Pathol. 2018 Apr;244(5):509-511. doi: 10.1002/path.5057.
10
The evolving genomic classification of lung cancer.肺癌的不断演变的基因组分类。
J Pathol. 2014 Jan;232(2):121-33. doi: 10.1002/path.4275.
引用本文的文献
1
Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.驱动基因定义的肺腺癌细胞系中 HSP90 的抑制：治疗疗效的关键蛋白。
Int J Mol Sci. 2023 Sep 7;24(18):13830. doi: 10.3390/ijms241813830.
2
Echinocystic acid induces the apoptosis, and inhibits the migration and invasion of non-small cell lung cancer cells.棘叶酸诱导非小细胞肺癌细胞凋亡，并抑制其迁移和侵袭。
Med Oncol. 2023 May 19;40(6):182. doi: 10.1007/s12032-023-02029-2.
3
The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth.钠/肌醇共转运蛋白 SLC5A3 促进非小细胞肺癌细胞生长。
Cell Death Dis. 2022 Jun 27;13(6):569. doi: 10.1038/s41419-022-05017-y.
4
A Pan-Canadian Validation Study for the Detection of T790M Mutation Using Circulating Tumor DNA From Peripheral Blood.一项使用外周血循环肿瘤DNA检测T790M突变的全加拿大验证研究。
JTO Clin Res Rep. 2021 Jul 13;2(8):100212. doi: 10.1016/j.jtocrr.2021.100212. eCollection 2021 Aug.
5
Downregulation of mA Reader YTHDC2 Promotes the Proliferation and Migration of Malignant Lung Cells via CYLD/NF-κB Pathway.m6A 读码器 YTHDC2 的下调通过 CYLD/NF-κB 通路促进恶性肺细胞的增殖和迁移。
Int J Biol Sci. 2021 Jun 22;17(10):2633-2651. doi: 10.7150/ijbs.58514. eCollection 2021.
6
miR-31 Displays Subtype Specificity in Lung Cancer.miR-31 在肺癌中显示出亚型特异性。
Cancer Res. 2021 Apr 15;81(8):1942-1953. doi: 10.1158/0008-5472.CAN-20-2769. Epub 2021 Feb 8.
7
snoRNAs Offer Novel Insight and Promising Perspectives for Lung Cancer Understanding and Management.snRNAs 为肺癌的理解和管理提供了新的视角和有前景的思路。
Cells. 2020 Feb 26;9(3):541. doi: 10.3390/cells9030541.
8
An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer.一种用于分析肺癌中DNA突变、基因融合和RNA表达的集成式下一代测序系统。
Transl Oncol. 2019 Jun;12(6):836-845. doi: 10.1016/j.tranon.2019.02.012. Epub 2019 Apr 12.
9
PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.丝氨酸蛋白酶 3/糜蛋白酶和激肽释放酶相关肽酶 5 与不良预后相关，并促进肺腺癌中的肿瘤细胞侵袭和生长。
Sci Rep. 2019 Feb 12;9(1):1844. doi: 10.1038/s41598-018-38362-0.
本文引用的文献
1
Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an Gene Fusion.一名具有 基因融合阳性的肺癌患者对克唑替尼产生显著反应。
JCO Precis Oncol. 2017;2017(1). doi: 10.1200/PO.17.00117. Epub 2017 Aug 29.
2
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
3
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
4
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.Keap1缺失促进Kras驱动的肺癌，并导致对谷氨酰胺分解代谢的依赖。
Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.
5
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.达克替尼对比吉非替尼作为 EGFR 突变阳性非小细胞肺癌患者的一线治疗（ARCHER 1050）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.
6
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.纵向分析小细胞肺癌患者的游离 DNA 可深入了解治疗效果和疾病复发的动态。
J Thorac Oncol. 2018 Jan;13(1):112-123. doi: 10.1016/j.jtho.2017.09.1951. Epub 2017 Sep 23.
7
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
8
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.对晚期 NSCLC 患者血液中 EGFR 突变进行大规模、前瞻性筛选，以指导治疗决策。
Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.
9
Putting p53 in Context.将p53置于背景中考虑。
Cell. 2017 Sep 7;170(6):1062-1078. doi: 10.1016/j.cell.2017.08.028.
10
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
Zotero 插件